Novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol acyltransferase inhibitors.

Bioorg Med Chem Lett

National Research Laboratory of Lipid Metabolism and Atherosclerosis, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, South Korea.

Published: June 2004

A series of pyrazoline derivatives were prepared for evaluating their acyl-CoA:cholesterol acyltransferase activities. 3-(3,5-Di-tert-butyl-4-hydroxyphenyl)-5-(multi-substituted 4-hydroxyphenyl)-2-pyrazolines 4a-i were shown in vitro inhibitory activity on hACAT-1 and -2.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2004.03.079DOI Listing

Publication Analysis

Top Keywords

acyl-coacholesterol acyltransferase
8
novel 35-diaryl
4
35-diaryl pyrazolines
4
pyrazolines human
4
human acyl-coacholesterol
4
acyltransferase inhibitors
4
inhibitors series
4
series pyrazoline
4
pyrazoline derivatives
4
derivatives prepared
4

Similar Publications

A positive correlation between cholesterol esterification and growth rate potential was previously found in our laboratory during the growth of CEM and MOLT4 lymphoblastic cells. In the current study, we investigated whether the rates of cholesterol esters synthesis correlate with changes of acyl-CoAcholesterol acyltransferase (ACAT) mRNA levels and of other genes implied in cholesterol biosynthesis and uptake, such as 3-hydroxy-3-methylglutaryl-CoA (HMGCoA) reductase and low density lipoprotein (LDL) receptor. The results showed that the more rapid growing CEM cells had lower levels of expression of HMGCoA-reductase and LDL receptors compared to MOLT4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!